

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l., (Holdings) Inc.**

**長江生命科技集團有限公司**

(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 0775)

## **BUSINESS UPDATE ON PRECLINICAL STUDY OF PRAME AND PD-L1 DUAL-ANTIGEN CANCER VACCINES**

CK Life Sciences Int'l., (Holdings) Inc. (the “Company”) announces that the Company will on 4 November 2023 present preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1) at the 2023 Society for Immunotherapy of Cancer Annual Meeting in San Diego, California, U.S.A.

The investigational cancer vaccines evaluated in the preclinical study contain antigenic sequences of PRAME and PD-L1 intended to induce anti-cancer immune responses. PRAME is a cancer antigen highly expressed in many different types of cancers and has been associated with different oncogenic processes. PD-L1 represents one of the most important immune checkpoint antigens highly expressed on cancer cells to limit T-cell activation in the tumour microenvironment.

In the preclinical study, the Company investigated whether dual-antigen cancer vaccines co-targeting PRAME and PD-L1 could suppress tumour growth in both prophylactic and therapeutic syngeneic mouse hepatocellular carcinoma models. The results of the preclinical data highlighted the potential of simultaneously targeting PRAME and PD-L1 by fusion protein vaccination in cancer immunotherapy.

The Company considers that the preclinical efficacy results of the dual-targeting PRAME and PD-L1 cancer vaccines in liver cancer are promising and the Company hopes to start clinical trials in the coming years. As liver cancer is the second most common cause of cancer death in Asia and remains a major unmet medical need, the Company plans to investigate the PRAME and PD-L1 dual-targeting cancer vaccines further in liver cancer and other cancer types known to over-express PRAME and PD-L1.

**It should be noted that the Company is only at the preclinical study stage and has not yet commenced clinical trials for the PRAME and PD-L1 dual-antigen cancer vaccines and accordingly, there is no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 1 November 2023

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).*